Global Medical REIT Quarterly Balance Sheets Chart
Quarterly
|
Annual
Global Medical REIT Quarterly Balance Sheets Table
Quarterly
|
Annual
Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||
investment in real estate: | ||||||||||||||||||||||||||||||||||||||
land | 173,123,000 | 173,293,000 | 174,300,000 | 168,110,000 | 162,391,000 | 164,315,000 | 164,315,000 | 164,315,000 | 165,242,000 | 167,285,000 | 168,308,000 | 168,289,000 | 165,045,000 | 155,529,000 | 152,060,000 | 149,249,000 | 145,424,000 | 133,040,000 | 128,857,000 | 116,123,000 | 104,316,000 | 101,715,000 | 95,381,000 | 86,878,000 | 76,831,000 | 68,326,000 | 63,710,000 | 56,839,000 | 55,330,000 | 52,301,000 | 42,701,000 | 36,839,127 | 25,822,453 | 23,130,337 | 17,785,001 | 11,733,852 | 7,043,852 | 7,043,852 |
building | 1,095,324,000 | 1,064,782,000 | 1,044,019,000 | 1,041,006,000 | 1,028,539,000 | 1,036,224,000 | 1,035,705,000 | 1,034,822,000 | 1,038,464,000 | 1,077,340,000 | 1,079,781,000 | 1,079,380,000 | 1,049,876,000 | 1,002,087,000 | 985,091,000 | 964,169,000 | 931,510,000 | 883,901,000 | 851,427,000 | 793,559,000 | 755,807,000 | 745,649,000 | 693,533,000 | 637,505,000 | 597,029,000 | 533,430,000 | 518,451,000 | 493,503,000 | 486,766,000 | 436,185,000 | 384,338,000 | 349,041,480 | 306,198,609 | 270,401,823 | 179,253,398 | |||
site improvements | 24,966,000 | 24,266,000 | 23,973,000 | 22,946,000 | 21,960,000 | 21,984,000 | 21,974,000 | 21,480,000 | 21,404,000 | 22,024,000 | 22,024,000 | 21,983,000 | 20,805,000 | 19,596,000 | 19,021,000 | 18,017,000 | 17,011,000 | 15,669,000 | 15,183,000 | 13,268,000 | 11,593,000 | 11,303,000 | 9,912,000 | 9,100,000 | 7,672,000 | 6,982,000 | 6,880,000 | 6,714,000 | 6,562,000 | 5,590,000 | 4,808,000 | 3,992,974 | 3,115,289 | 2,686,216 | 1,465,273 | |||
tenant improvements | 80,019,000 | 75,023,000 | 69,679,000 | 66,933,000 | 66,004,000 | 67,021,000 | 66,358,000 | 65,772,000 | 66,544,000 | 66,375,000 | 65,987,000 | 65,004,000 | 62,500,000 | 60,154,000 | 58,900,000 | 56,156,000 | 53,730,000 | 50,596,000 | 49,204,000 | 46,965,000 | 41,891,000 | 37,044,000 | 33,909,000 | 31,465,000 | 27,371,000 | 16,206,000 | 15,357,000 | 14,328,000 | 12,189,000 | 9,201,000 | 8,010,000 | 5,095,651 | 2,996,662 | 2,552,449 | 1,186,014 | |||
acquired lease intangible assets | 147,376,000 | 141,828,000 | 138,945,000 | 137,886,000 | 136,394,000 | 138,617,000 | 138,617,000 | 138,617,000 | 139,715,000 | 148,249,000 | 148,077,000 | 147,836,000 | 146,339,000 | 130,790,000 | 127,931,000 | 123,918,000 | 112,649,000 | 103,269,000 | 98,234,000 | 91,465,000 | 83,269,000 | 78,977,000 | 72,794,000 | 65,498,000 | 54,698,000 | 43,987,000 | 43,152,000 | 41,653,000 | 41,162,000 | 34,034,000 | 31,650,000 | 27,308,632 | 17,218,214 | 15,991,981 | 7,144,276 | |||
| 1,520,808,000 | 1,479,192,000 | 1,450,916,000 | 1,436,881,000 | 1,415,288,000 | 1,428,161,000 | 1,426,969,000 | 1,425,006,000 | 1,431,369,000 | 1,481,273,000 | 1,484,177,000 | 1,482,492,000 | 1,444,565,000 | 1,368,156,000 | 1,343,003,000 | 1,311,509,000 | 1,260,324,000 | 1,186,475,000 | 1,142,905,000 | 1,061,380,000 | 996,876,000 | |||||||||||||||||
less: accumulated depreciation and amortization | -316,649,000 | -301,190,000 | -288,921,000 | -283,941,000 | -271,764,000 | -262,287,000 | -247,503,000 | -232,518,000 | -218,109,000 | -213,690,000 | -198,218,000 | -182,255,000 | -172,006,000 | -157,132,000 | -143,255,000 | -130,284,000 | -117,720,000 | -105,779,000 | -94,462,000 | -83,893,000 | -73,979,000 | -64,635,000 | -56,503,000 | -48,731,000 | -41,882,000 | -35,771,000 | -30,625,000 | -26,839,000 | -22,026,000 | -17,420,000 | -13,594,000 | -10,142,823 | ||||||
investment in real estate | 1,204,159,000 | 1,178,002,000 | 1,161,995,000 | 1,152,940,000 | 1,143,524,000 | 1,165,874,000 | 1,179,466,000 | 1,192,488,000 | 1,213,260,000 | 1,267,583,000 | 1,285,959,000 | 1,300,237,000 | 1,272,559,000 | 1,211,024,000 | 1,199,748,000 | 1,181,225,000 | 1,142,604,000 | 1,080,696,000 | 1,048,443,000 | 977,487,000 | 922,897,000 | 910,053,000 | 849,026,000 | 781,715,000 | 721,719,000 | 633,160,000 | 616,925,000 | 586,198,000 | 579,983,000 | 519,891,000 | 457,913,000 | 412,135,041 | 331,612,458 | 294,100,857 | 196,365,771 | 122,311,086 | 92,152,179 | 92,696,181 |
cash and cash equivalents | 6,580,000 | 5,412,000 | 6,815,000 | 5,723,000 | 4,978,000 | 1,333,000 | 1,278,000 | 1,281,000 | 2,460,000 | 4,603,000 | 4,016,000 | 3,199,000 | 5,873,000 | 1,854,000 | 7,213,000 | 6,030,000 | 5,821,000 | 5,304,000 | 5,507,000 | 2,052,000 | 8,392,000 | 11,340,000 | 2,765,000 | 2,815,000 | 3,216,000 | 1,844,000 | 3,631,000 | 3,005,000 | 4,755,000 | 3,351,000 | 5,109,000 | |||||||
restricted cash | 2,646,000 | 2,176,000 | 2,127,000 | 2,066,000 | 2,840,000 | 6,473,000 | 5,446,000 | 6,331,000 | 7,325,000 | 9,378,000 | 10,439,000 | 10,396,000 | 8,327,000 | 6,336,000 | 5,546,000 | 5,839,000 | 6,549,000 | 6,096,000 | 5,246,000 | 5,210,000 | 4,945,000 | 5,536,000 | 4,420,000 | 3,011,000 | 2,656,000 | 1,464,000 | 1,212,000 | 817,000 | 1,432,000 | 4,050,000 | 2,005,000 | 2,040,026 | 2,291,080 | 1,773,909 | 941,344 | 805,776 | 977,578 | 1,277,831 |
tenant receivables | 7,826,000 | 8,104,000 | 7,424,000 | 8,122,000 | 8,073,000 | 7,743,000 | 6,762,000 | 7,527,000 | 7,381,000 | 7,402,000 | 8,040,000 | 6,382,000 | 6,189,000 | 6,477,000 | 6,070,000 | 5,126,000 | 4,886,000 | 5,585,000 | 5,596,000 | 6,702,000 | 5,888,000 | 5,708,000 | 4,957,000 | 4,167,000 | 3,935,000 | 3,559,000 | 2,905,000 | 1,744,000 | 1,339,000 | 1,253,000 | 704,000 | 616,741 | 534,484 | 347,110 | 212,435 | 177,369 | 261,955 | |
due from related parties | 461,000 | 420,000 | 270,000 | 404,000 | 410,000 | 363,000 | 193,000 | 289,000 | 391,000 | 321,000 | 200,000 | 337,000 | 337,000 | 451,000 | 163,000 | 275,000 | 265,000 | 229,000 | 103,000 | 121,000 | 124,000 | 70,000 | 50,000 | 75,000 | ||||||||||||||
escrow deposits | 556,000 | 915,000 | 711,000 | 1,694,000 | 925,000 | 737,000 | 673,000 | 9,861,000 | 9,725,000 | 8,625,000 | 7,833,000 | 7,660,000 | 7,708,000 | 7,697,000 | 5,957,000 | 5,970,000 | 5,531,000 | 5,163,000 | 4,817,000 | 3,792,000 | 3,301,000 | 3,589,000 | 3,417,000 | 2,865,000 | 3,518,000 | 3,296,000 | 1,752,000 | 2,628,000 | 2,080,000 | 2,508,000 | 1,638,000 | 1,297,665 | 979,709 | 2,528,996 | 1,212,177 | 903,636 | 945,162 | 889,519 |
deferred assets | 28,672,000 | 28,251,000 | 28,208,000 | 27,685,000 | 28,360,000 | 27,995,000 | 27,132,000 | 26,748,000 | 26,189,000 | 30,322,000 | 29,616,000 | 28,667,000 | 27,731,000 | 26,714,000 | 25,417,000 | 24,422,000 | 23,050,000 | 21,676,000 | 20,272,000 | 18,928,000 | 17,433,000 | 16,141,000 | 14,512,000 | 13,307,000 | 11,831,000 | 10,358,000 | 9,352,000 | 8,590,000 | 7,200,000 | 5,171,000 | 3,993,000 | 2,923,494 | 1,867,010 | 1,087,148 | 704,537 | 245,619 | 1,735,973 | 436,068 |
derivative asset | 10,396,000 | 13,713,000 | 18,613,000 | 14,967,000 | 27,672,000 | 29,285,000 | 25,125,000 | 38,379,000 | 35,864,000 | 27,428,000 | 34,705,000 | 36,926,000 | 16,583,000 | 12,692,000 | 1,236,000 | 219,000 | 137,000 | 136,000 | 2,194,000 | |||||||||||||||||||
goodwill | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | 5,903,000 | ||||||||||||||||||
investment in unconsolidated joint venture | 1,917,000 | 1,992,000 | 2,066,000 | |||||||||||||||||||||||||||||||||||
other assets | 27,843,000 | 24,667,000 | 22,354,000 | 23,091,000 | 18,530,000 | 17,874,000 | 15,722,000 | 13,713,000 | 12,302,000 | 7,473,000 | 6,550,000 | 7,042,000 | 6,056,000 | 6,345,000 | 6,232,000 | 8,297,000 | 5,219,000 | 5,530,000 | 5,019,000 | 5,356,000 | 3,587,000 | 3,731,000 | 3,593,000 | 4,363,000 | 3,847,000 | 3,009,000 | 322,000 | 1,109,000 | 2,283,000 | 527,000 | 459,000 | 160,214 | 88,695 | 11,484 | 140,374 | |||
total assets | 1,296,959,000 | 1,269,555,000 | 1,256,486,000 | 1,242,595,000 | 1,241,215,000 | 1,263,580,000 | 1,267,700,000 | 1,302,520,000 | 1,320,800,000 | 1,369,038,000 | 1,393,261,000 | 1,406,749,000 | 1,357,266,000 | 1,285,493,000 | 1,263,485,000 | 1,243,306,000 | 1,199,965,000 | 1,136,318,000 | 1,100,906,000 | 1,025,551,000 | 966,567,000 | 956,168,000 | 884,934,000 | 812,318,000 | 750,722,000 | 656,690,000 | 636,099,000 | 604,091,000 | 602,027,000 | 539,856,000 | 474,571,000 | 428,927,663 | 369,395,591 | 325,768,465 | 227,319,130 | 205,791,478 | 98,385,696 | 96,096,760 |
liabilities and equity | ||||||||||||||||||||||||||||||||||||||
liabilities: | ||||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 3,768 and 4,868 at june 30, 2025 and december 31, 2024, respectively | 698,832,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 4 and 22 at june 30, 2025 and december 31, 2024, respectively | 14,153,000 | |||||||||||||||||||||||||||||||||||||
accounts payable and accrued expenses | 19,006,000 | 14,519,000 | 16,468,000 | 13,350,000 | 11,962,000 | 10,520,000 | 12,781,000 | 13,300,000 | 15,457,000 | 12,604,000 | 13,819,000 | 13,100,000 | 11,922,000 | 9,272,000 | 10,344,000 | 11,065,000 | 8,080,000 | 7,230,000 | 7,279,000 | 8,329,000 | 8,836,000 | 7,144,000 | 5,069,000 | 5,501,000 | 4,224,000 | 3,385,000 | 3,664,000 | 4,420,000 | 5,494,000 | 4,125,000 | 2,020,000 | 2,433,549 | 2,216,953 | 1,932,590 | 573,997 | |||
dividends payable | 11,985,000 | 16,597,000 | 16,520,000 | 16,534,000 | 16,280,000 | 16,157,000 | 16,134,000 | 16,055,000 | 16,048,000 | 15,854,000 | 15,821,000 | 15,777,000 | 15,926,000 | 15,823,000 | 15,668,000 | 15,309,000 | 15,251,000 | 14,482,000 | 12,470,000 | 11,843,000 | 11,281,000 | 10,949,000 | 11,091,000 | 9,470,000 | 9,081,000 | 8,985,000 | 6,981,000 | 6,109,000 | 5,940,000 | 5,826,000 | 5,638,000 | 4,767,037 | 3,700,936 | 3,651,817 | 3,604,037 | 3,592,786 | ||
security deposits | 3,407,000 | 3,374,000 | 3,324,000 | 3,222,000 | 3,973,000 | 4,376,000 | 3,688,000 | 3,913,000 | 4,213,000 | 4,688,000 | 5,461,000 | 5,404,000 | 5,304,000 | 4,616,000 | 4,540,000 | 4,600,000 | 4,385,000 | 4,367,000 | 2,099,844 | 719,592 | 597,593 | 319,499 | 319,499 | |||||||||||||||
other liabilities | 18,438,000 | 16,030,000 | 14,191,000 | 12,370,000 | 12,809,000 | 12,952,000 | 12,770,000 | 12,138,000 | 12,137,000 | 8,226,000 | 7,363,000 | 6,848,000 | 7,428,000 | 7,090,000 | 7,709,000 | 7,104,000 | 5,983,000 | 6,793,000 | 6,171,000 | |||||||||||||||||||
acquired lease intangible liability | 6,117,000 | 3,902,000 | 3,936,000 | 3,638,000 | 4,149,000 | 4,713,000 | 5,281,000 | 5,860,000 | 6,444,000 | 7,028,000 | 7,613,000 | 8,220,000 | 7,903,000 | 8,161,000 | 8,128,000 | 8,333,000 | 8,437,000 | 7,998,000 | 8,222,000 | 8,621,000 | 5,598,000 | 3,425,000 | 3,164,000 | 3,287,000 | 2,778,000 | 2,004,000 | 2,028,000 | 2,034,000 | 2,081,000 | 1,488,000 | 1,291,000 | 1,080,123 | 1,112,566 | 475,343 | 277,917 | |||
total liabilities | 771,938,000 | 731,452,000 | 700,570,000 | 677,989,000 | 662,843,000 | 666,482,000 | 661,886,000 | 668,872,000 | 679,408,000 | 740,563,000 | 744,196,000 | 742,165,000 | 708,157,000 | 632,876,000 | 625,908,000 | 613,081,000 | 562,710,000 | 540,499,000 | 643,146,000 | 576,344,000 | 523,858,000 | 517,378,000 | 424,581,000 | 440,875,000 | 389,119,000 | 286,128,000 | 336,349,000 | 349,435,000 | 346,514,000 | 285,113,000 | 215,558,000 | 175,900,856 | 193,092,997 | 176,513,596 | 72,290,752 | 46,083,186 | 86,250,769 | 83,346,083 |
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||
equity: | ||||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
common stock | 67,000 | 67,000 | 67,000 | 67,000 | 66,000 | 66,000 | 66,000 | 66,000 | 66,000 | 66,000 | 66,000 | 66,000 | 66,000 | 65,000 | 65,000 | 64,000 | 64,000 | 61,000 | 49,000 | 48,000 | 46,000 | 44,000 | 44,000 | 36,000 | 35,000 | 35,000 | 26,000 | 22,000 | 22,000 | 22,000 | 22,000 | 21,631 | ||||||
additional paid-in capital | 734,290,000 | 734,290,000 | 734,223,000 | 733,626,000 | 722,627,000 | 722,623,000 | 722,418,000 | 722,418,000 | 722,418,000 | 722,113,000 | 721,991,000 | 722,074,000 | 722,074,000 | 720,306,000 | 711,414,000 | 700,206,000 | 700,038,000 | 648,949,000 | 504,789,000 | 487,114,000 | 462,607,000 | 440,220,000 | 433,330,000 | 340,435,000 | 322,872,000 | 322,359,000 | 243,038,000 | 208,938,000 | 205,788,000 | 205,788,000 | 205,788,000 | 207,268,720 | 202,513,240 | 172,417,006 | 171,997,396 | 171,143,411 | 18,010,613 | 18,010,613 |
accumulated deficit | -316,510,000 | -305,677,000 | -293,736,000 | -281,067,000 | -268,885,000 | -251,963,000 | -238,984,000 | -224,375,000 | -213,744,000 | -211,794,000 | -198,706,000 | -185,316,000 | -179,614,000 | -168,089,000 | -157,017,000 | -147,562,000 | -138,088,000 | -127,480,000 | -116,773,000 | -107,943,000 | -88,037,000 | -78,990,000 | -71,389,000 | -63,846,000 | -57,397,000 | -51,390,000 | -45,007,000 | -46,855,000 | -42,739,000 | -38,349,000 | -34,434,000 | -29,914,472 | -26,231,752 | -23,179,743 | -16,986,624 | -11,452,725 | -5,877,113 | -5,261,363 |
accumulated other comprehensive income | 10,396,000 | 13,713,000 | 18,613,000 | 14,967,000 | 27,672,000 | 29,285,000 | 25,125,000 | 38,379,000 | 35,859,000 | 27,410,000 | 34,674,000 | 36,883,000 | 16,527,000 | 10,757,000 | ||||||||||||||||||||||||
total global medical reit inc. stockholders' equity | 503,202,000 | 517,352,000 | 534,126,000 | 542,552,000 | 556,439,000 | 574,970,000 | 583,584,000 | 611,447,000 | 619,558,000 | 612,754,000 | 632,984,000 | 648,666,000 | 634,012,000 | 637,998,000 | 622,785,000 | 615,721,000 | 623,189,000 | 581,901,000 | 444,805,000 | 434,527,000 | 415,601,000 | 430,270,000 | 340,988,000 | 331,176,000 | 269,295,000 | 236,955,000 | 238,030,000 | 242,420,000 | 246,335,000 | 252,334,882 | ||||||||
noncontrolling interest | 21,819,000 | 20,751,000 | 21,790,000 | 22,054,000 | 21,933,000 | 22,128,000 | 22,230,000 | 22,201,000 | 21,834,000 | 15,721,000 | 16,081,000 | 15,918,000 | 15,097,000 | 14,619,000 | 14,792,000 | 14,504,000 | 14,066,000 | 13,918,000 | 12,955,000 | 14,680,000 | 14,788,000 | 23,189,000 | 30,083,000 | 30,455,000 | 30,427,000 | 30,342,000 | 30,455,000 | 17,701,000 | 17,483,000 | 12,323,000 | 12,678,000 | 691,925 | ||||||
total equity | 525,021,000 | 538,103,000 | 555,916,000 | 564,606,000 | 578,372,000 | 597,098,000 | 605,814,000 | 633,648,000 | 641,392,000 | 628,475,000 | 649,065,000 | 664,584,000 | 649,109,000 | 652,617,000 | 637,577,000 | 630,225,000 | 637,255,000 | 595,819,000 | 457,760,000 | 449,207,000 | 442,709,000 | 438,790,000 | 460,353,000 | 371,443,000 | 361,603,000 | 259,013,000 | 253,026,807 | |||||||||||
total liabilities and equity | 1,296,959,000 | 1,269,555,000 | 1,256,486,000 | 1,242,595,000 | 1,241,215,000 | 1,263,580,000 | 1,267,700,000 | 1,302,520,000 | 1,320,800,000 | 1,369,038,000 | 1,393,261,000 | 1,406,749,000 | 1,357,266,000 | 1,285,493,000 | 1,263,485,000 | 1,243,306,000 | 1,199,965,000 | 1,136,318,000 | 1,100,906,000 | 1,025,551,000 | 966,567,000 | 956,168,000 | 884,934,000 | 812,318,000 | 750,722,000 | |||||||||||||
credit facility, net of unamortized debt issuance costs of 4,318 and 4,868 at march 31, 2025 and december 31, 2024, respectively | 662,782,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 13 and 22 at march 31, 2025 and december 31, 2024, respectively | 14,248,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2025 and december 31, 2024, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 4,868 and 7,067 at december 31, 2024 and december 31, 2023, respectively | 631,732,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 22 and 66 at december 31, 2024 and december 31, 2023, respectively | 14,399,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at december 31, 2024 and december 31, 2023, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 5,418 and 7,067 at september 30, 2024 and december 31, 2023, respectively | 614,382,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 31 and 66 at september 30, 2024 and december 31, 2023, respectively | 14,493,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at september 30, 2024 and december 31, 2023, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 5,968 and 7,067 at june 30, 2024 and december 31, 2023, respectively | 599,032,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 40 and 66 at june 30, 2024 and december 31, 2023, respectively | 14,638,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2024 and december 31, 2023, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 6,518 and 7,067 at march 31, 2024 and december 31, 2023, respectively | 592,082,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 53 and 66 at march 31, 2024 and december 31, 2023, respectively | 25,682,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2024 and december 31, 2023, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 7,067 and 9,253 at december 31, 2023 and december 31, 2022, respectively | 585,333,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 66 and 452 at december 31, 2023 and december 31, 2022, respectively | 25,899,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at december 31, 2023 and december 31, 2022, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 7,617 and 9,253 at september 30, 2023 and december 31, 2022, respectively | 560,783,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 337 and 452 at september 30, 2023 and december 31, 2022, respectively | 56,823,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at september 30, 2023 and december 31, 2022, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 8,155 and 9,253 at june 30, 2023 and december 31, 2022, respectively | 567,988,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 375 and 452 at june 30, 2023 and december 31, 2022, respectively | 57,121,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2023 and december 31, 2022, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 8,704 and 9,253 at march 31, 2023 and december 31, 2022, respectively | 634,796,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 413 and 452 at march 31, 2023 and december 31, 2022, respectively | 57,367,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2023 and december 31, 2022, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 9,253 and 8,033 at december 31, 2022 and december 31, 2021, respectively | 636,447,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 452 and 607 at december 31, 2022 and december 31, 2021, respectively | 57,672,000 | |||||||||||||||||||||||||||||||||||||
derivative liability | 1,865,000 | 7,790,000 | 12,070,000 | 13,814,000 | 14,603,000 | 18,086,000 | 19,505,000 | 21,495,000 | 20,461,000 | 8,685,000 | 10,399,000 | 9,083,000 | 5,520,000 | 3,487,000 | ||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at december 31, 2022 and december 31, 2021, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 9,802 and 8,033 at september 30, 2022 and december 31, 2021, respectively | 634,898,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 491 and 607 at september 30, 2022 and december 31, 2021, respectively | 57,918,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at september 30, 2022 and december 31, 2021, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 7,113 and 8,033 at june 30, 2022 and december 31, 2021, respectively | 602,987,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 530 and 607 at june 30, 2022 and december 31, 2021, respectively | 56,687,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2022 and december 31, 2021, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 7,570 and 8,033 at march 31, 2022 and december 31, 2021, respectively | 529,130,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 568 and 607 at march 31, 2022 and december 31, 2021, respectively | 56,919,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2022 and december 31, 2021, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 8,033 and 3,559 at december 31, 2021 and december 31, 2020, respectively | 514,567,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 607 and 835 at december 31, 2021 and december 31, 2020, respectively | 57,162,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at december 31, 2021 and december 31, 2020, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
accumulated other comprehensive loss | -6,636,000 | -11,946,000 | -13,784,000 | -14,588,000 | -18,219,000 | -19,651,000 | -21,654,000 | -20,632,000 | -6,674,000 | -10,596,000 | -9,293,000 | -5,743,000 | -3,721,000 | -109,000 | ||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 8,497 and 3,559 at september 30, 2021 and december 31, 2020, respectively | 497,203,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 644 and 835 at september 30, 2021 and december 31, 2020, respectively | 57,397,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at september 30, 2021 and december 31, 2020, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 8,960 and 3,559 at june 30, 2021 and december 31, 2020, respectively | 442,140,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 706 and 835 at june 30, 2021 and december 31, 2020, respectively | 64,620,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2021 and december 31, 2020, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 3,284 and 3,559 at march 31, 2021 and december 31, 2020, respectively | 420,216,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 772 and 835 at march 31, 2021 and december 31, 2020, respectively | 64,810,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2021 and december 31, 2020, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 3,559 and 3,832 at december 31, 2020 and december 31, 2019, respectively | 521,641,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 835 and 667 at december 31, 2020 and december 31, 2019, respectively | 64,937,000 | |||||||||||||||||||||||||||||||||||||
security deposits and other | 4,340,000 | 5,571,000 | 5,814,000 | 6,546,000 | 6,351,000 | 6,362,000 | 5,881,000 | 4,122,000 | 4,152,000 | 3,928,000 | 5,052,000 | 4,912,000 | 2,128,000 | 2,206,145 | 2,444,842 | |||||||||||||||||||||||
due to related party | 1,957,000 | 1,948,000 | 1,648,000 | |||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at december 31, 2020 and december 31, 2019, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 3,875 and 3,832 at september 30, 2020 and december 31, 2019, respectively | 454,325,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 898 and 667 at september 30, 2020 and december 31, 2019, respectively | 65,060,000 | |||||||||||||||||||||||||||||||||||||
other liability | 3,090,000 | 2,417,000 | 2,414,000 | 2,405,000 | 2,379,000 | 2,371,000 | 2,367,000 | |||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at september 30, 2020 and december 31, 2019, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 3,350 and 3,832 at june 30,2020 and december 31, 2019, respectively | 415,850,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 668 and 667 at june 30,2020 and december 31, 2019, respectively | 50,610,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2020 and december 31, 2019, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
total global medical reit inc. stockholders’ equity | 427,921,000 | 340,220,000 | ||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 3,607 and 3,832 at march 31, 2020 and december 31, 2019, respectively | 425,843,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 634 and 667 at march 31, 2020 and december 31, 2019, respectively | 38,648,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2020 and december 31, 2019, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized debt issuance costs of 3,832 and 3,922 at december 31, 2019 and 2018, respectively | 347,518,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized debt issuance costs of 667 and 799 at december 31, 2019 and 2018, respectively | 38,650,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at december 31, 2019 and 2018, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized discount of 3,983 and 3,922 at september 30, 2019 and december 31, 2018, respectively | 363,242,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 701 and 799 at september 30, 2019 and december 31, 2018, respectively | 38,651,000 | |||||||||||||||||||||||||||||||||||||
due to related parties | 1,584,000 | 1,358,000 | 1,100,000 | 1,030,000 | 1,028,000 | 987,000 | 1,035,000 | 1,036,000 | 802,286 | 638,790 | 586,899 | 580,911 | 1,135,302 | 2,493,401 | 1,068,562 | |||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at september 30, 2019 and december 31, 2018, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized discount of 3,784 and 3,922 at june 30, 2019 and december 31, 2018, respectively | 315,691,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 733 and 799 at june 30, 2019 and december 31, 2018, respectively | 38,652,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2019 and december 31, 2018, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||
credit facility, net of unamortized discount of 3,682 and 3,922 at march 31, 2019 and december 31, 2018, respectively | 219,993,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 766 and 799 at march 31, 2019 and december 31, 2018, respectively | 38,652,000 | |||||||||||||||||||||||||||||||||||||
stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2019 and december 31, 2018, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
total stockholders’ equity | 370,562,000 | 299,750,000 | 254,656,000 | 255,513,000 | 254,743,000 | |||||||||||||||||||||||||||||||||
total liabilities and stockholders’ equity | 656,690,000 | |||||||||||||||||||||||||||||||||||||
revolving credit facility, net of unamortized discount of 3,922 and 2,750 at december 31, 2018 and 2017, respectively | 276,353,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 799 and 930 at december 31, 2018 and 2017, respectively | 38,654,000 | |||||||||||||||||||||||||||||||||||||
stockholders' equity: | ||||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at december 31, 2018 and 2017, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
total liabilities and stockholders' equity | 636,099,000 | 604,091,000 | 602,027,000 | 539,856,000 | 474,571,000 | 428,927,663 | 369,395,591 | 325,768,465 | 227,319,130 | 205,791,478 | 98,385,696 | 96,096,760 | ||||||||||||||||||||||||||
revolving credit facility, net of unamortized discount of 4,127 and 2,750 at september 30, 2018 and december 31, 2017, respectively | 293,273,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 832 and 930 at september 30, 2018 and december 31, 2017, respectively | 38,643,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at september 30, 2018 and december 31, 2017 | 74,959,000 | |||||||||||||||||||||||||||||||||||||
deferred financing costs | 2,955,000 | 3,105,000 | 2,750,000 | 2,977,981 | 2,770,144 | 1,570,381 | 927,085 | |||||||||||||||||||||||||||||||
revolving credit facility | 288,350,000 | 229,150,000 | 164,900,000 | 126,100,000 | 144,500,000 | 128,900,000 | 27,700,000 | |||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 865 and 930 at june 30, 2018 and december 31, 2017, respectively | 38,610,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at june 30, 2018 and december 31, 2017 | 74,959,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 898 and 930 at march 31, 2018 and december 31, 2017, respectively | 38,577,000 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at march 31, 2018 and december 31, 2017 | 74,959,000 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 930 and 1,062 at december 31, 2017 and 2016, respectively | 38,545,000 | |||||||||||||||||||||||||||||||||||||
notes payable to related parties | 421,000 | 421,000 | 421,000 | |||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000 shares authorized; 3,105 and no shares issued and outstanding at december 31, 2017 and 2016, respectively | 74,959,000 | |||||||||||||||||||||||||||||||||||||
cash | 6,776,501 | 12,033,797 | 8,356,599 | 19,671,131 | 81,347,992 | 2,574,804 | 507,281 | |||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 963,184 and 1,061,602 at september 30, 2017 and december 31, 2016, respectively | 38,511,716 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000,000 shares authorized; 3,105,000 and no shares issued and outstanding at september 30, 2017 and december 31, 2016, respectively | 74,959,003 | |||||||||||||||||||||||||||||||||||||
less: accumulated depreciation | -6,520,555 | -4,669,968 | -3,323,915 | -2,517,532 | -1,932,083 | -1,388,081 | ||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 995,990 and 1,061,602 at june 30, 2017 and december 31, 2016, respectively | 38,478,910 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||
common stock 0.001 par value, 500,000,000 shares authorized at june 30, 2017 and december 31, 2016, respectively; 21,105,675 and 17,605,675 shares issued and outstanding at june 30, 2017 and december 31, 2016, respectively | 21,106 | |||||||||||||||||||||||||||||||||||||
total stockholders' equity | 176,302,594 | 149,254,869 | 155,028,378 | 159,708,292 | 12,134,927 | 12,750,677 | ||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 1,028,797 and 1,061,602 at march 31, 2017 and december 31, 2016, respectively | 38,446,103 | |||||||||||||||||||||||||||||||||||||
common stock 0.001 par value, 500,000,000 shares authorized at march 31, 2017 and december 31, 2016, respectively; 17,605,675 shares issued and outstanding at march 31, 2017 and december 31, 2016, respectively | 17,606 | |||||||||||||||||||||||||||||||||||||
convertible debenture, due to related party | ||||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 1,061,602 and 302,892 at december 31, 2016 and december 31, 2015, respectively | 38,413,298 | |||||||||||||||||||||||||||||||||||||
stockholders' equity | ||||||||||||||||||||||||||||||||||||||
common stock 0.001 par value, 500,000,000 shares authorized at december 31, 2016 and december 31, 2015, respectively; 17,605,675 and 250,000 shares issued and outstanding at december 31, 2016 and december 31, 2015, respectively | 17,606 | |||||||||||||||||||||||||||||||||||||
building and improvements | 113,094,766 | 87,040,410 | 87,040,410 | |||||||||||||||||||||||||||||||||||
accrued expenses | 416,230 | 3,078,078 | 1,568,004 | |||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 1,177,522 and 302,892 at september 30, 2016 and december 31, 2015, respectively | 39,920,275 | |||||||||||||||||||||||||||||||||||||
common stock 0.001 par value, 500,000,000 shares authorized at september 30, 2016 and december 31, 2015, respectively; 17,605,675 and 250,000 shares issued and outstanding at september 30, 2016 and december 31, 2015, respectively | 17,606 | |||||||||||||||||||||||||||||||||||||
convertible debenture, due to majority stockholder | 25,030,134 | 25,030,134 | ||||||||||||||||||||||||||||||||||||
note payable to majority stockholder | 421,000 | 421,000 | ||||||||||||||||||||||||||||||||||||
note payable to related party | 450,000 | 450,000 | ||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 1,240,126 and 302,892 at june 30, 2016 and december 31, 2015, respectively | 54,458,657 | |||||||||||||||||||||||||||||||||||||
common stock 0.001 par value, 500,000,000 shares authorized at june 30, 2016 and december 31, 2015, respectively; 1,426,656 and 250,000 shares issued and outstanding at june 30, 2016 and december 31, 2015, respectively | 1,427 | |||||||||||||||||||||||||||||||||||||
prepaid assets | 27,925 | |||||||||||||||||||||||||||||||||||||
notes payable, net of unamortized discount of 1,302,730 and 302,892, respectively | 54,488,884 | |||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value, 100,000,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||
common stock 0.001 par value, 500,000,000 shares authorized at march 31, 2016 and december 31, 2015, respectively; 1,426,656 and 250,000 shares issued and outstanding at march 31, 2016 and december 31, 2015, respectively | 1,427 |
We provide you with 20 years of balance sheets for Global Medical REIT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Global Medical REIT. Explore the full financial landscape of Global Medical REIT stock with our expertly curated balance sheets.
The information provided in this report about Global Medical REIT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.